Nialamide
From Wikipedia, the free encyclopedia
 |
|
|---|---|
| Systematic (IUPAC) name | |
| N-benzyl-3-(N'-(pyridine-4-carbonyl)hydrazino)propanamide | |
| Clinical data | |
| AHFS/Drugs.com | International Drug Names |
| Pregnancy cat. | ? |
| Legal status | Uncontrolled |
| Routes | Oral |
| Identifiers | |
| CAS number | 51-12-7  |
| ATC code | N06AF02 |
| PubChem | CID 4472 |
| DrugBank | DB04820 |
| ChemSpider | 4317 |
| UNII | T2Q0RYM725 |
| KEGG | D07337 |
| Chemical data | |
| Formula | C16H18N4O2 |
| Mol. mass | 298.34 g/mol |
| SMILES | eMolecules & PubChem |
|
|
 (what is this?) (verify) |
Nialamide (Niamid) is an irreversible and non-selective monoamine oxidase inhibitor (MAOI) of the hydrazine chemical class used as an antidepressant and anxiolytic. Along with phenelzine and isocarboxazid, it is one of the few hydrazine MAOIs still in clinical use.[citation needed]
Contents |
[edit] Indications
[edit] Depression
Nialamide
[edit] Miscellaneous
Nialamide is sometimes used in the treatment of trigeminal neuralgia, generalized anxiety disorder and social phobia. It has also been studied for alcoholism,[1] dermatomally distributed vitiligo,[2] irregular menstruation,[3] angina,[4] cerebrovascular disorders,[5] and the prevention of streptomycin-induced deafness.[6]
[edit] Side effects
Side effects on central nervous system include euphoria, psychomotor agitation, insomnia, anxiety, headache, vertigo, tremor, hyperreflexia, manic state, or turnig a depression into mania in bipolar disorder. Other side effects are arterial hypotension, orthostatic hypotension, arterial hypertension, palpitations, hyperhidrosis, dry mouth, nausea, vomiting, epigastric pain, constipation, vision problems, retrobulbar optic neuritis, polyneuritis, weight gain, acute cardiac insufficiency, tachycardia, peripheral neuropathy, jaundice, hepatomegaly, hyperbilirubinemia, urinary retention, elevated transaminases, cutaneous eruptions, impotence, and delayed ejaculation. Dangerous side effects are drug-induced hepatitis and hepatocellular insufficiency.
[edit] See also
[edit] References
- ^ Bobrov AE, Shurygin AN, Krasil'nikov SB (1991). "[Effectiveness of combined use of monoamine oxidase inhibitors and psychotherapy in the treatment of chronic alcoholism]". Zhurnal Nevropatologii i Psikhiatrii Imeni SS Korsakova. 91 (2): 79–83. PMID 1647635.
- ^ Koga M (1977). "Vitiligo: a new classification and therapy". British Journal of Dermatology 97 (3): 255–61. doi:10.1111/j.1365-2133.1977.tb15180.x. PMID 921895.
- ^ Gautray JP, Jolivet A (1976). "[Neuroendocrine investigation and therapy of the menstrual cycle disorders (author's transl)(proceedings)]". Annales d'endocrinologie 37 (4): 293–4. PMID 1022189.
- ^ Barats SS, Oranskii IE, Kartashova DI, Gorovater EN (1976). "[Comparative clinico-physiological study of the effect of several MAO inhibitors in stenocardia]". Kardiologiia 16 (3): 138–40. PMID 1021625.
- ^ Mirzoian RS (1975). "[Prevention of cerebrovascular disorders with adrenergic substances]". Biulleten' Eksperimental'noi Biologii i Meditsiny 80 (11): 50–3. PMID 1218262.
- ^ Semczuk B, Klonowski S, Golabek W (1974). "The protective effect of niamid on hearing in patients treated with large doses of streptomycin". Annales Universitatis Mariae Curie-Sklodowska Sectio D: Medicina 29 (1): 193–7. PMID 4467804.
|
|
|
|
|
|
